METASTATIC HER2-NEGATIVE BREAST CANCER
Clinical trials for METASTATIC HER2-NEGATIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new METASTATIC HER2-NEGATIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for METASTATIC HER2-NEGATIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail aims to tackle tough breast cancer
Disease control Recruiting nowThis study tests a new drug called JSKN016, given with chemotherapy or immunotherapy, for people with HER2-negative breast cancer that cannot be removed by surgery or has spread. The trial includes 180 adults in China and aims to see if the combination shrinks tumors and how safe…
Matched conditions: METASTATIC HER2-NEGATIVE BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd • Aim: Disease control
Last updated Jun 26, 2026 18:35 UTC
-
New study seeks to improve quality of life for advanced breast cancer patients
Symptom relief Recruiting nowThis study tracks how patients with metastatic triple-negative breast cancer feel during treatment with sacituzumab govitecan or standard chemotherapy. Researchers will measure changes in quality of life and symptoms using patient questionnaires. The goal is to see which treatmen…
Matched conditions: METASTATIC HER2-NEGATIVE BREAST CANCER
Sponsor: Fudan University • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC